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Intermittent Recurrent Renal Failure:

Diagnosing Atypical Hemolytic Uremic Syndrome
SE Davis, DO, PJ Dunn, DO, RS Schreiner, DO

Department of Internal Medicine, Lehigh Valley Health Network Allentown, Pennsylvania

Introduction

Hemolytic uremic syndrome (HUS) is characterized
by the clinical triad of microangiopathic hemolytic
anemia, thrombocytopenia, and acute kidney injury.
Atypical Hemolytic Uremic Syndrome (aHUS) refers
to non-Shiga-toxin HUS and is a primary thrombotic
microangiopathic disease due to chronic, uncontrolled
activation of the complement system. Complementmediated HUS is a relatively rare, life threatening
disorder caused by mutations in the genes that
encode complement proteins.

Case Report
A 68 year-old male with a past medical history of three previous hospitalizations
for unexplained acute renal failure presented with fever, chills and a transient
rash on his forearms. On admission his serum creatinine was 0.95mg/dl. He
quickly developed anuric renal failure with a rapidly rising creatinine requiring
initiation of hemodialysis. Peripheral smear demonstrated schistocytes. Labs
revealed thrombocytopenia, anemia, and hypocomplementemia. A renal
biopsy was performed which demonstrated features of membranoproliferative
glomerulonephritis and thrombotic microangiopathy. Initial therapy included high
dose steroids and the initiation of plasmapheresis, however he has since been
started on Eclizumab.

Discussion
The diagnosis of complement-mediated HUS remains
challenging and is based on the clinical presentation of
microangiopathic hemolytic anemia, thrombocytopenia, and
acute kidney injury, not meeting criteria for typical HUS and
1
TTP. Mutations in proteins that regulate the alternative
complement pathway such as Factor H (CFH), membrane
cofactor protein (MCP or CD46), and Factor I (IF) have been
2
implicated in causing aHUS. In the past, plasma exchange
was first line treatment however Eculizumab, a humanized
monoclonal antibody to C5, has now been shown to more
3
effective resulting in decreased morbidity.
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